263 related articles for article (PubMed ID: 35211591)
21. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
22. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
[TBL] [Abstract][Full Text] [Related]
23. [A case report of TAFRO syndrome].
Zhou GP; Zhou QY; Zhu JH
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):814-817. PubMed ID: 34393252
[TBL] [Abstract][Full Text] [Related]
24. Castleman disease and TAFRO syndrome.
Masaki Y; Arita K; Sakai T; Takai K; Aoki S; Kawabata H
Ann Hematol; 2022 Mar; 101(3):485-490. PubMed ID: 35044513
[TBL] [Abstract][Full Text] [Related]
25. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
Front Immunol; 2019; 10():1489. PubMed ID: 31316523
[No Abstract] [Full Text] [Related]
26. International definition of iMCD-TAFRO: future perspectives.
Nishimura Y; Nishimura MF; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
[TBL] [Abstract][Full Text] [Related]
27. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
[TBL] [Abstract][Full Text] [Related]
28. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
[TBL] [Abstract][Full Text] [Related]
29. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
[TBL] [Abstract][Full Text] [Related]
30. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
Sumiyoshi R; Koga T; Fukui S; Furukawa K; Momoki M; Ichinose K; Yano S; Kawakami A
Clin Immunol; 2023 Nov; 256():109798. PubMed ID: 37778714
[TBL] [Abstract][Full Text] [Related]
31. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus Treatment for TAFRO Syndrome.
Shirai T; Ichikawa S; Saegusa J
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791031
[TBL] [Abstract][Full Text] [Related]
33. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
[TBL] [Abstract][Full Text] [Related]
36. TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient.
Miatech JL; Patel NR; Latuso NQ; Ellipeddi PK
Cureus; 2019 Jun; 11(6):e4946. PubMed ID: 31453020
[TBL] [Abstract][Full Text] [Related]
37. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
38. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
39. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease.
Butzmann A; Kumar J; Sridhar K; Gollapudi S; Ohgami RS
Biology (Basel); 2021 Mar; 10(4):. PubMed ID: 33804823
[TBL] [Abstract][Full Text] [Related]
40. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
